Immtech Pharmaceuticals Immtech company immtach investors Immtech business development Immtech contact Immtech technology Immtech pipeline
Immtech drug discovery program  
Immtech Hepatitis C Immtech Bacterial Immtech fungal diseases  

 

Fungal diseases

A growing threat
The market for effective antifungal medications is growing because of the increasing number of patients who are susceptible to infection.

The market for an effective antifungal drug has been estimated at US$4 billion annually.
Due to the increasing number of patients susceptible to fungal diseases, including
people treated with chemotherapy, people living with HIV, and patients who have
undergone organ transplants, that number is expected to grow. Additionally, fungal
infection is now the third most common cause of sepsis in hospital patients -- more
prevalent than Escherichia coli (E. coli).

Recently, new strains of fungi have emerged which are resistant to currently available
treatments. There are significant commercial opportunities for new drugs effective
against these strains, as well as for drugs with broad-spectrum effectiveness for
Candida and Aspergillus infections.

In in vitro studies, our consortium scientists have identified several compounds that
display broad-based antifungal activity against Candida, Aspergillus and Cryptococcus
fungi. From these studies, we have identified a lead group of compounds that display
significant in vitro activity against both drug-sensitive and drug-resistant strains of
fungi.

 

Terms of Use | Privacy Policy
© 2008 Immtech. All Rights Reserved